Hemophilia A in children: prophylaxis, physical activity and rehabilitation in the prevention of hemophilic arthropathy
DOI:
https://doi.org/10.12775/JEHS.2026.91.71503Keywords
hemophilia A, hemophilic arthropathy, bleeding prophylaxis, pediatric physiotherapy, physical activity, HJHS scaleAbstract
Background: Hemophilia A is a rare X-linked genetic disorder characterized by a deficiency of coagulation factor VIII. A key clinical problem in children is recurrent joint bleeding (hemarthrosis), which leads to the development of chronic synovitis and progressive hemophilic arthropathy, the main cause of disability in this patient population.
Aim: The aim of this study is to present the significance of modern bleeding prophylaxis, systematic physical activity, and physiotherapy in preventing musculoskeletal complications in children with hemophilia.
Material and methods: An analysis of current literature and guidelines regarding replacement therapy (factor VIII concentrates) and non-factor therapy (emicizumab) was performed. The use of functional diagnostic tools was discussed, including the Hemophilia Joint Health Score (HJHS 2.1), functional performance tests (6MWT, TUG), goniometry, and modern methods of objective assessment of muscle strength and posture.
Results: The introduction of early bleeding prophylaxis allows for a significant reduction in the number of joint bleeds. Physical activity, especially low-impact types (swimming, cycling), enhances dynamic joint stabilization by strengthening the muscular corset and improving proprioception. Contemporary physiotherapy, based on progressive resistance training and biofeedback, is safe and essential for maintaining musculoskeletal function, while objective diagnostics enable early detection of subclinical joint changes.
Conclusions: Effective prevention of hemophilic arthropathy in children requires an integrated interdisciplinary approach. The combination of modern pharmacological treatment with regular physical activity and functional rehabilitation allows pediatric patients to achieve functional capacity comparable to their peers and minimizes the risk of permanent disability.
References
1. Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. sierpnia 2020;26(S6):1–158. doi:10.1111/hae.14046
2. Stonebraker JS, Bolton‐Maggs PHB, Michael Soucie J, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia. stycznia 2010;16(1):20–32. doi:10.1111/j.1365-2516.2009.02127.x
3. Rodriguez-Merchan EC. Musculoskeletal complications of hemophilia. HSS J Musculoskelet J Hosp Spec Surg. lutego 2010;6(1):37–42. doi:10.1007/s11420-009-9140-9 PubMed PMID: 19921342; PubMed Central PMCID: PMC2821487.
4. Gelbenegger G, Schoergenhofer C, Knoebl P, Jilma B. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A. Thromb Haemost. października 2020;120(10):1357–70. doi:10.1055/s-0040-1714279 PubMed PMID: 32717759; PubMed Central PMCID: PMC7649063.
5. Lenting PJ, Christophe OD, Denis CV. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood. 26 marca 2015;125(13):2019–28. doi:10.1182/blood-2014-06-528406 PubMed PMID: 25712991.
6. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemoph Off J World Fed Hemoph. grudnia 2006;12 Suppl 6:15–22. doi:10.1111/j.1365-2516.2006.01361.x PubMed PMID: 17123389.
7. Windyga J. Zaburzenia hemostazy : postępy 2023/2024 / Jerzy Windyga. W: MP Medycyna Praktyczna. 2023.
8. Matsushita T, Shapiro A, Abraham A, Angchaisuksiri P, Castaman G, Cepo K, et al. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. N Engl J Med. 31 sierpnia 2023;389(9):783–94. doi:10.1056/NEJMoa2216455
9. Concizumab – Zastosowanie w terapii i aktualne badania kliniczne. Europejska Sieć Informacji o Badaniach Klinicznych [Internet]. [cytowane 3 kwietnia 2026]. Dostępne na: https://badaniakliniczne.pl/lek/concizumab/
10. Marstacimab – Zastosowanie w terapii i aktualne badania kliniczne. Europejska Sieć Informacji o Badaniach Klinicznych [Internet]. [cytowane 3 kwietnia 2026]. Dostępne na: https://badaniakliniczne.pl/lek/marstacimab/
11. Atilla B, Güney-Deniz H. Musculoskeletal treatment in haemophilia. EFORT Open Rev. czerwca 2019;4(6):230–9. doi:10.1302/2058-5241.4.180068
12. Bordbar M, Beigipour R, Tahami M, Zekavat OR, Haghpanah S, Moshfeghinia R. Skeletal complications in patients with hemophilia: a single-center experience. J Orthop Surg. 29 listopada 2023;18(1):907. doi:10.1186/s13018-023-04409-w
13. Lassandro G, Accettura D, Giordano P. Promoting Sports Practice in Persons with Hemophilia: A Survey of Clinicians’ Perspective. Int J Environ Res Public Health. 11 listopada 2021;18(22):11841. doi:10.3390/ijerph182211841 PubMed PMID: 34831596; PubMed Central PMCID: PMC8625842.
14. Linari S, Castaman G. Hemophilia: changes and new achievements in management and care. Int J Bone Fragility. 1 października 2025;5(2):66–71. doi:10.57582/IJBF.250502.066
15. Bliss LS, Teeple P. Core stability: The centerpiece of any training program. Curr Sports Med Rep. 1 maja 2005;4(3):179–83. doi:10.1007/s11932-005-0064-y
16. Willson JD, Dougherty CP, Ireland ML, Davis IM. Core stability and its relationship to lower extremity function and injury. J Am Acad Orthop Surg. września 2005;13(5):316–25. doi:10.5435/00124635-200509000-00005 PubMed PMID: 16148357.
17. Hilberg T, Herbsleb M, Gabriel HH, Jeschke D, Schramm W. Proprioception and isometric muscular strength in haemophilic subjects. Haemoph Off J World Fed Hemoph. listopada 2001;7(6):582–8. doi:10.1046/j.1365-2516.2001.00563.x PubMed PMID: 11851757.
18. Gönen T, Yakut Y, Akbayram S. The effects of close kinetic chain exercises on proprioception and physical activity level in pediatric patients with hemophilia. Haemophilia. 2022;28(6):e189–98. doi:10.1111/hae.14645
19. Howell C, Scott K, Patel DR. Sports participation recommendations for patients with bleeding disorders. Transl Pediatr. lipca 2017;6(3):174–80. doi:10.21037/tp.2017.04.07 PubMed PMID: 28795008; PubMed Central PMCID: PMC5532193.
20. Anderson A, Forsyth A. Playing It Safe: Bleeding Disorders, Sports and Exercise [Internet]. New York: National Hemophilia Foundation; 2017. Dostępne na: https://stepsforliving.hemophilia.org
21. Guzmann K, Wilczyński B, Jaskulak M, Radoń-Proskura J, Szarmach A, Mital A, et al. Eight-Week Resistance Training and Manual Therapy in Young Patients with Severe Hemophilia: A Case Series Evaluating Functional, Imaging, and Immunological Outcomes. J Clin Med. 27 listopada 2025;14(23):8419. doi:10.3390/jcm14238419 PubMed PMID: 41375720; PubMed Central PMCID: PMC12692835.
22. Timmer MA, Kloek CJJ, de Kleijn P, Kuijlaars IAR, Schutgens REG, Veenhof C, et al. A Blended Physiotherapy Intervention for Persons With Hemophilic Arthropathy: Development Study. J Med Internet Res. 19 czerwca 2020;22(6):e16631. doi:10.2196/16631 PubMed PMID: 32558654; PubMed Central PMCID: PMC7334756.
23. Kuijlaars IAR, van der Net J, Feldman BM, Aspdahl M, Bladen M, de Boer W, et al. Evaluating international Haemophilia Joint Health Score (HJHS) results combined with expert opinion: Options for a shorter HJHS. Haemophilia. listopada 2020;26(6):1072–80. doi:10.1111/hae.14180 PubMed PMID: 33058441; PubMed Central PMCID: PMC7821332.
24. Calatayud J, Pérez-Alenda S, Carrasco JJ, Cruz-Montecinos C, Andersen LL, Bonanad S, et al. Safety and Effectiveness of Progressive Moderate-to-Vigorous Intensity Elastic Resistance Training on Physical Function and Pain in People With Hemophilia. Phys Ther. 31 sierpnia 2020;100(9):1632–44. doi:10.1093/ptj/pzaa106 PubMed PMID: 32525975.
25. Tat AM, Tat NM, Sekeroz S, Buke M, Karaman K. Low frequency physiotherapy on joint health, hemarthrosis, walking, balance and reaction time in hemophilic arthropathy: a controlled trial. BMC Musculoskelet Disord. 4 kwietnia 2025;26:332. doi:10.1186/s12891-025-08549-4 PubMed PMID: 40186132; PubMed Central PMCID: PMC11971827.
26. Fearn M, Hill K, Williams S, Mudge L, Walsh C, McCarthy P, et al. Balance dysfunction in adults with haemophilia. Haemoph Off J World Fed Hemoph. 1 lipca 2010;16(4):606–14. doi:10.1111/j.1365-2516.2010.02200.x PubMed PMID: 20331756.
27. Falk B, Portal S, Tiktinsky R, Zigel L, Weinstein Y, Constantini N, et al. Bone properties and muscle strength of young haemophilia patients. Haemoph Off J World Fed Hemoph. lipca 2005;11(4):380–6. doi:10.1111/j.1365-2516.2005.01116.x PubMed PMID: 16011592.
28. Terapia genowa w hemofilii – punkt widzenia klinicysty. Terapie Genowe [Internet]. [cytowane 26 kwietnia 2026]. Dostępne na: https://terapiegenowe.pl/terapia-genowa-w-hemofilii-punkt-widzenia-klinicysty/
29. FDA zatwierdziła terapię genową Beqvez w hemofilii B. Hemostaza.edu.pl [Internet]. [cytowane 26 kwietnia 2026]. Dostępne na: https://hemostaza.edu.pl/aktualnosci/news/id/1018-fda-zatwierdzila-terapie-genowa-beqvez-w-hemofilii-b
30. Chang YH, Cheng CF, Chen SM, Cheng SN, Chen YC, Liu TC, et al. Gene therapy for hemophilia, a clinical viewpoint. J Chin Med Assoc. 2023;86(7):641–7. doi:10.1097/JCMA.0000000000000947 PubMed PMID: 37210312.
31. Herzog RW, Kaczmarek R, High KA. Gene therapy for hemophilia – From basic science to first approvals of “one-and-done” therapies. Mol Ther. 2025;33(5):2015–34. doi:10.1016/j.ymthe.2025.03.043 PubMed PMID: 40156189.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Michał Lubkowski, Zuzanna Leciej, Krzysztof Antczak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 20
Number of citations: 0
